Category: Cardiometabolic
-
REMODEL’s Primary Kidney-Imaging Endpoints Were Null. The “Mechanism” Story Comes From Secondary and Exploratory Layers Instead
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers two peer-reviewed randomized trials of incretin-axis drugs, both industry-sponsored. Every number below is attributed to its source tier — peer-reviewed full text, a public trial registry, or a sponsor statistical…
-
Lp(a)HORIZON: A Missed Primary Endpoint, a Press Release, and the Numbers That Are Still Missing
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a corporate topline announcement about a completed cardiovascular outcomes trial in a listed company’s pivotal asset. Every result-layer number below is attributed as a company statement; trial design, population, and…
-
Two Gates in Heart Failure: A Drug That Bound Its Target and Still Failed, and One That Passed Its Trial and Still Split on Reimbursement
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. This piece covers two separate, publicly documented events in the same disease area: a completed, peer-reviewed phase 2b trial (not a simulation, not a preprint) and two national health-technology-assessment…
-
A Heart-Failure Combination-Therapy Calculator Built From 38,753 Patients — and the Prediction-Interval Distinction That Decides What It Actually Tells You
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The study discussed below is a peer-reviewed pooled individual-participant-data analysis of nine randomized trials, published in Nature Medicine. It estimates short-term changes in blood pressure, kidney function, and potassium…
-
Aficamten Met Both Primary Endpoints in Nonobstructive HCM. Its Effect Size Nearly Overlaps With the Trial That Didn’t
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. Both trials discussed below are peer-reviewed, randomized, double-blind, placebo-controlled phase 3 trials published in the New England Journal of Medicine. The comparison drawn between them is an indirect, cross-trial…
-
Blocking the Clot Is Not Protecting the Brain: An Unpeer-Reviewed UK Biobank Preprint on Atrial Fibrillation and Brain Health (n=502,099)
Correction, 2026-09-08. This piece originally stated that whether the authors adjusted for kidney function was unconfirmed, and that the plasma NfL finding could therefore not be separated from renal confounding. That was wrong, and the answer was in the preprint all along: its main text reports that results were unaltered by further adjustment for estimated…
-
A million exomes point at FNIP1 — and at how narrow the window for hitting it may be
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. An exome-sequencing analysis of 1,032,116 people across America, Europe and Asia tested rare protein-coding variants against the triglyceride-to-HDL ratio, used as a biomarker of energy state…
-
Finerenone across CKM stages — the relative effect is flat, the absolute benefit is not, and the new endpoint moves its own goalposts
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A post hoc analysis of 12,990 people with type 2 diabetes and chronic kidney disease from two phase 3 trials, pooled and then re-classified using the…
-
Retatrutide in early type 2 diabetes — the glucose axis converges, the weight axis does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 537 adults with early type 2 diabetes inadequately controlled on diet and exercise (mean duration 2.5 years, HbA1c 7.9%, BMI 35.8), 40 weeks of once-weekly…
-
MASLD non-invasive tests — fibrosis staging clears the bar, the MASH treatment gate does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In a prospective, multicenter cohort with centrally read liver biopsy as the reference standard (LITMUS Imaging Study, N = 357, Nature Medicine, published online July 24,…
